YOLFTbeta
Pulse Biosciences Inc

Pulse Biosciences Inc

PLSE · NASDAQ · Healthcare / Medical Instruments & Supplies

50.44USD-1.81 (-3.46%)

Price History

Full chart

Market Stats

Previous Close52.25
Open52.53
Day Range50.20 – 54.25
52-Week Range12.56 – 58.90
Volume590.11K
Market Cap3.68B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.17
Dividend Yield0.00%
Beta1.63
50-Day Avg44.42
200-Day Avg26.63

About

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Paul Arthur LaViolette M.B.A.
  • Employees116
  • Headquarters601 Brickell Key Drive, Miami, FL, United States, 33131, USA
  • Websitehttps://www.pulsebiosciences.com

Leadership

  • Mr. Paul Arthur LaViolette M.B.A.President, CEO & Co-Chairman of the Board · b. 1958
  • Mr. Jon SkinnerChief Financial Officer · b. 1986
  • Mr. Darrin R. UeckerCTO & Director · b. 1966
  • Ms. Liane TeplitskyChief Operating Officer · b. 1977
  • Mr. Steven T. WeberVP of Accounting, Principal Accounting Officer & Global Corporate Controller · b. 1976
  • Mr. Kenneth B. Stratton Esq., J.D.General Counsel & Corporate Secretary · b. 1969
  • Ms. Patty PerlaVice President of Human Resources
  • Mr. David DanitzSenior Vice President of Engineering
  • Dr. Gansevoort Dunnington M.D.Chief Medical Officer
  • Dr. Niv Ad M.D.Chief Science Officer of Cardiac Surgery

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0068.00K247.00K00114.00K1.42M700.00K-9.00K0350.00K
Growth (%)---+263.24%-100.00%--+1143.86%-50.63%-101.29%+100.00%-
Cost of Revenue00665.00K665.00K665.00K666.00K1.09M1.97M11.94M1.21M1.18M1.61M
Gross Profit00-665.00K-665.00K-665.00K-666.00K-1.09M-550.00K-11.24M-1.21M-1.18M-1.26M
Gross Margin---977.94%-269.23%---960.53%-38.79%-1606.29%13411.11%--360.00%
Operating Expense308.57K4.47M8.92M25.15M37.30M47.29M48.87M62.46M46.81M42.37M55.08M75.68M
Operating Income-308.57K-4.47M-9.59M-25.81M-37.96M-47.95M-49.97M-63.01M-58.06M-43.57M-56.26M-76.94M
Operating Margin---14097.06%-10451.01%---43828.95%-4443.86%-8293.86%484155.56%--21982.57%
EBITDA-108.00K-3.75M-8.83M-24.57M-36.65M-46.79M-48.87M-61.87M-56.70M-39.90M-52.41M-71.71M
EBITDA Margin---12980.88%-9945.75%---42868.42%-4363.05%-8100.29%443366.67%--20488.57%
Net Income-474.86K-2.81M-9.52M-25.57M-37.55M-45.99M-49.74M-63.16M-58.95M-42.21M-53.59M-72.78M
Net Income Margin---13997.06%-10351.01%---43628.95%-4454.16%-8421.86%469000.00%--20794.57%
R&D44.57K2.58M5.99M9.65M17.25M24.96M26.44M28.64M20.84M27.80M32.34M44.72M
R&D as % of Total Revenue--8805.88%3905.26%--23196.49%2019.75%2977.00%-308855.56%-12777.43%
Interest Expense0000000646.00K448.00K1.10M--
Interest Expense % of Total Revenue--0.00%0.00%--0.00%45.56%64.00%-12222.22%--

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets17.90M14.33M26.31M49.82M70.64M41.91M41.29M54.25M77.88M59.15M132.46M96.11M
Total Liabilities1.82M659.76K1.02M3.83M4.31M11.18M18.40M18.56M80.13M14.79M17.60M15.46M
Total Equity16.07M13.67M25.30M45.99M66.33M30.74M22.89M35.69M-2.25M44.36M114.86M80.66M
Cash7.01M3.61M2.09M3.39M51.10M6.90M12.46M28.61M61.14M44.37M118.04M80.73M
Total Debt-----6.72M11.36M11.25M75.96M9.14M8.90M7.53M
Net Debt-7.01M-3.61M-2.09M-3.39M-51.10M-180.00K-1.11M-17.36M14.82M-35.22M-109.14M-73.20M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-173.14K-3.32M-8.05M-11.09M-23.90M-34.19M-35.37M-54.10M-47.01M-33.04M-36.34M-54.12M
Investing Cash Flow-77.14K-86.03K-14.38M-23.00M26.12M-10.10M10.04M7.56M-401.00K-121.00K-125.00K-335.00K
Financing Cash Flow12.27M20.91M20.91M35.38M45.50M82.00K30.89M62.69M79.94M16.39M110.14M17.15M
Capital Expenditure78.86K86.03K64.00K2.55M276.00K608.00K441.00K437.00K401.00K121.00K125.00K315.00K
Free Cash Flow-252.00K-3.40M-8.12M-13.64M-24.17M-34.79M-35.81M-54.53M-47.41M-33.16M-36.47M-54.44M
Dividends Paid--00-619.00K-810.00K----
FCF to OCF145.54%102.59%100.79%123.01%101.16%101.78%101.25%100.81%100.85%100.37%100.34%100.58%
Dividend Paid to FCF--0.00%0.00%--1.78%--1.49%----

Earnings

Report DateJun 30, 2016Nov 14, 2016Mar 14, 2017May 4, 2017Jul 27, 2017Nov 8, 2017Mar 16, 2018May 8, 2018Jul 31, 2018Nov 28, 2018Feb 7, 2019Apr 30, 2019Aug 8, 2019Nov 7, 2019Mar 16, 2020May 11, 2020Aug 10, 2020Nov 9, 2020Feb 22, 2021May 10, 2021Aug 9, 2021Nov 15, 2021Mar 31, 2022May 11, 2022Aug 10, 2022Nov 10, 2022Mar 30, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Mar 28, 2024May 7, 2024Aug 19, 2024Oct 30, 2024Mar 26, 2025May 5, 2025Aug 12, 2025Nov 5, 2025Feb 19, 2026May 4, 2026Aug 6, 2026Nov 4, 2026
EPS Estimate-----------0.51-0.44-0.51-0.61-0.61-0.47-0.50-0.44-0.45-0.49-0.52-0.53-0.51-0.52-0.40-0.45-0.24-0.22-0.24-0.22-0.24-0.24-0.20-0.24-0.24--0.26-0.31-0.21-0.22-0.31-0.35
EPS Actual-0.23-0.21-0.21-0.23-0.43-0.52-0.52-0.51-0.54-0.64-0.51-0.49-0.55-0.57-0.66-0.57-0.53-0.51-0.54-0.44-0.48-0.48-0.52-0.58-0.44-0.49-0.25-0.26-0.22-0.19-0.22-0.18-0.20-0.21-0.31-0.25-0.28-0.29-0.18-0.24-0.36-
Surprise----------0.00%-11.36%-7.84%6.56%-8.20%-21.28%-6.00%-15.91%-20.00%10.20%7.69%9.43%-1.96%-11.54%-10.00%-8.89%-4.17%-18.18%8.33%13.64%9.71%25.00%0.45%13.50%-30.17%--7.69%6.45%14.29%-9.73%-16.13%-
Timing----------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap3.68B
Enterprise Value3.61B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales3107.50
Price / Book37.20
EPS-1.17
Book Value1.41
Revenue (TTM)1.19M
Gross Profit (TTM)3.00K
EBITDA-82.62M
Profit Margin0.00%
Operating Margin-5823.04%
Return on Equity-78.49%
Return on Assets-44.34%
Shares Outstanding71.32M
Shares Float20.65M
Beta1.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
15.43%
Insiders
71.05%
Retail / Other
13.52%

Top Institutional Holders

  • BlackRock Inc
    1.34M1.88%
  • Bank of America Corp
    866.06K1.21%
  • Vanguard Capital Management, LLC
    815.85K1.14%
  • Portolan Capital Management, LLC
    733.37K1.03%
  • Citadel Advisors Llc
    626.51K0.88%
  • Geode Capital Management, LLC
    491.95K0.69%
  • Massachusetts Financial Services Company
    462.90K0.65%
  • State Street Corp
    456.93K0.64%
  • Balyasny Asset Management LLC
    265.16K0.37%
  • Hovey Youngman Associates Inc
    227.28K0.32%
  • LMR Partners LLP
    213.14K0.30%
  • Northern Trust Corp
    187.27K0.26%
  • Vanguard Portfolio Management, LLC
    165.20K0.23%

Top Fund Holders

  • T. Rowe Price New Horizons
    737.61K1.03%
  • Vanguard MStar Total Stk Mkt Idx Invest
    554.61K0.78%
  • iShares Russell 2000 ETF
    479.88K0.67%
  • Strategic Advisers U.S. Total Stock
    454.41K0.64%
  • MFS New Discovery I
    339.45K0.48%
  • Fidelity Small Cap Index
    201.66K0.28%
  • iShares Russell 2000 Growth ETF
    175.60K0.25%